About: Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: $97.56 (+2.50%)
KNSA NASDAQ Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd share price
Atividade de preço de KNSA
Último preço
$ 97,560
Variação (24h)
2,38 USD (2,50%)
Volume
1.37M
Volume (média 4 sem.)
-
Abertura
$ 95,00
Variação do dia
$ 94,40 - $ 98,36
Fechamento anterior
$ 95,18
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
KNSA price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals